Repligen | RGEN - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
Agilent USD 990M 44M 2026-03
Align Technology USD 736.59M 53M 2026-03
Bio Techne USD 208.29M 17.01M 2026-03
BioMarin Pharmaceutical USD 571.21M 141.8M 2026-03
Bristol-Myers Squibb USD 8.41B 381M 2025-12
Bruker USD 379.8M 69.4M 2026-03
Charles River Laboratories USD 279.32M 7.36M 2026-03
Danaher USD 3.59B 375M 2026-03
Dentsply International USD 427M 16M 2026-03
General Electric Aerospace USD 4.24B 439M 2026-03
Henry Schein USD 1.07B 7M 2026-03
Illumina USD 721M 38M 2026-03
IQVIA Holdings USD 1.07B 52M 2026-03
Mettler Toledo International USD 675.44M 65.98M 2025-12
Myriad Genetics USD 146.8M 3M 2025-12
OraSure Technologies USD 11.34M 435K 2025-12
Pacific Biosciences Of California USD 15.74M 601K 2025-12
Pfizer USD 11.04B 1.24B 2026-03
Repligen USD 108.28M 4.45M 2026-03
Revvity USD 387.66M 34M 2026-03
Standard Biotools USD 11.38M 1.9M 2025-12
Thermo Fisher Scientific USD 4.49B 146M 2026-03
Waters USD 542M 15.42M 2026-03
West Pharmaceutical Services USD 296.4M 7.5M 2026-03